JNJ250103C167500
- 0.00
- 0.000.00%
Johnson & Johnson Newsroom
Johnson & Johnson (JNJ.US) announced positive results from the Phase 3 trial of its dual antibody frontline combination therapy, which can improve the overall survival of cancer patients.
Evaluate the efficacy and safety of the combination of Rybrevant and Lazcluze compared to the active control osimertinib.
RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $181
J&J Rybrevant/Lazcluze Combo Bests AstraZeneca's Tagrisso in NSCLC
Johnson & Johnson Drug Combination Shows Positive Results in Lung Cancer Study
Johnson & Johnson Announces RYBREVANT Plus LAZCLUZE Show Statistically Significant And Clinically Meaningful Improvement In Overall Survival Versus Osimertinib; Median Overall Survival Improvement Expected To Exceed One Year; First And Only Regimen...
Express News | Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze™ (Lazertinib) Show Statistically Significant and Clinically Meaningful Improvement in Overall Survival Versus Osimertinib
Express News | J&J: Median Overall Survival Improvement With Rybrevant Plus Lazcluze Expected to Exceed One Year
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Best Income Ideas for 2025: Stocks, Bonds, and Everything in Between
Dividend Roundup: Johnson & Johnson, JPMorgan, Oracle, Mastercard, and More
Johnson & Johnson To Go Ex-Dividend On February 18th, 2025 With 1.24 USD Dividend Per Share
January 2nd (Eastern Time) - $Johnson & Johnson(JNJ.US)$ is trading ex-dividend on February 18th, 2025.Shareholders of record on February 18th, 2025 will receive 1.24 USD dividend per share on March 4
U.S. Companies With Potential Pension Risk Transfer Restructuring Opportunities
5 Low-Leverage Stocks Worth Adding to Your Portfolio in 2025
Smart Money Is Betting Big In JNJ Options
Johnson & Johnson Declares $1.24 Quarterly Dividend; 3.4% Yield
Press Release: Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025
Express News | Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025
After experiencing a bumper harvest in 2024, the USA ETF may encounter setbacks this year.
The USA Exchange Traded Fund (ETF) received a record inflow of $1.1 trillion in 2024, but entering 2025, rapid growth may face more obstacles.
Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
Johnson & Johnson (JNJ.US) has applied for the market launch of its innovative compound drug "Mexitentan Tadalafil Tablets" in China for the treatment of pulmonary arterial hypertension.
The CDE website shows that Johnson & Johnson (JNJ.US) has submitted an application for the innovative compound drug "Maqitengtan Tadalafil Tablets" to be marketed domestically for the treatment of pulmonary arterial hypertension (PAH).